CIEL_en

CIEL The CIEL project (Immune escape and innate immunity in lymphoma), builds on the important research work previously carried out by the team on the mechanisms of immune escape (IE) in malignant lymphomas, and in particular on the development of a multiparametric...

LUNG-RESIST_en

LUNG-RESIST Lung cancer is the major cause of cancer-related death in France and worldwide. In the past few years, patients with specific genetic alterations such as mutations in the EGFR gene (about 15% of lung adenocarcinomas, 45% in non-smokers), have benefited...

MELANICa_en

MELANICa Immunotherapies have revolutionised the therapeutic management of melanoma by increasing the immune response against this dreaded skin cancer. However, not all patients respond to immunotherapies and some relapse within two years following treatment...

Comm’in BCen

Comm’in BC The role of the tumor immune microenvironment has been poorly investigated in breast cancer (BC) and particularly in estrogen receptor positive (ER+) low-grade luminal A and high-grade luminal B subsets. Tissue-resident memory cells (TRM), a subset of...

LMSTARen

LMSTAR Leiomyosarcomas (LMS) are among the most common sarcomas and their prognosis is still poor. No effective systemic treatment has been identified so far and surgery remains the mainstay of management. Their oncogenesis remains poorly understood. To decipher this...

Pin It on Pinterest

Centre de Recherches en Cancérologie de Toulouse
Privacy Policy

To improve your browsing experience. Cookies provide information on how the site is used: statistics such as the number of visitors, the average length of visits or the number of pages viewed. On the other hand, disabling cookies may prevent you from using certain features, such as sharing content via social networks.
By clicking "Accept", you agree to the use of cookies from this site and to our privacy policy.

You can adjust all your cookie settings by navigating the tabs on the left.